Isolated CNS progression in EGFR/ALK NSCLC while on third-generation CNS penetrant drug, new CNS mutation is non-targetable (CV 5c) standard or high dose TKI to follow. This evidence concerns the gene EGFR and non-small cell lung carcinoma.